Poland based biotech player, Ryvu Therapeutics has launched Keelira, a dedicated early clinical development services business designed to help biotechnology and pharmaceutical companies advance oncology programmes into Europe.

Based in Poland, Keelira will support sponsors from clinical-entry preparation through Phase I and Phase II development, with a focus on oncology, haematological malignancies and rare cancers.

Its capabilities include regulatory strategy, development planning, site selection, clinical execution and multi-country patient recruitment across European markets.

Keelira was initially developed within Ryvu to support the advancement of its own oncology pipeline and was subsequently applied to external clinical collaborations, including Phase II studies and multi-country site activation and patient enrolment.

The company operates a CRO Plus model, combining clinical execution with strategic advisory and central laboratory capabilities.

Its strategic advisory services integrate regulatory, CMC and data-readiness planning with clinical execution, while its Central Lab currently provides GCLP-compliant sample management and storage, with plans to expand into PK, PD and biomarker analysis.

Kamil Sitarz, PhD, General Manager, Keelira, said the company aims to provide sponsors with a coordinated team covering regulatory strategy, development planning, site selection and clinical execution while allowing sponsors to retain control over their assets and key strategic decisions.

Keelira builds on Ryvu’s established investigator network, including relationships with more than 70 oncology sites in Poland, over 20 in Spain, and more than 15 each in France and Italy.

The launch positions Keelira to support emerging biotech and pharma companies seeking to enter European clinical development and accelerate early-stage oncology programmes across multiple countries.